Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

FDMT

4D Molecular Therapeutics Inc

Dec 13 • 04:00PM ET

6.50

Dollar change -0.38
Percentage change -5.52	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB SRPT CRSP NTLA EDIT BLUE ARWR SGMO

| Held by: VTI IWM XBI VXF IWO VTWO IBB SCHA IWN IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.73	Insider Own	17.53%	Shs Outstand	52.00M	Perf Week	-11.56%
Market Cap	283.88M	Forward P/E	-	EPS next Y	-3.61	Insider Trans	-0.45%	Shs Float	38.13M	Perf Month	-15.69%
Income	-95.93M	PEG	-	EPS next Q	-0.84	Inst Own	111.56%	Short Float	22.35%	Perf Quarter	-60.56%
Sales	21.99M	P/S	12.91	EPS this Y	-13.07%	Inst Trans	-20.40%	Short Ratio	9.30	Perf Half Y	-72.49%
Book/sh	10.63	P/B	0.61	EPS next Y	-23.78%	ROA	-29.90%	Short Interest	8.52M	Perf Year	-59.38%
Cash/sh	11.49	P/C	0.57	EPS next 5Y	-	ROE	-33.00%	52W Range	6.63 - 36.25	Perf YTD	-67.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.35%	ROI	-16.75%	52W High	-82.07%	Beta	2.74
Dividend TTM	-	Quick Ratio	17.33	Sales past 5Y	111.29%	Gross Margin	74.42%	52W Low	-1.96%	ATR (14)	0.51
Dividend Ex-Date	-	Current Ratio	17.33	EPS Y/Y TTM	17.81%	Oper. Margin	-477.24%	RSI (14)	32.34	Volatility	6.00% 7.90%
Employees	147	Debt/Eq	0.04	Sales Y/Y TTM	1014.45%	Profit Margin	-436.30%	Recom	1.64	Target Price	45.70
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-2.15%	Payout	-	Rel Volume	1.02	Prev Close	6.88
Sales Surprise	-99.81%	EPS Surprise	-16.88%	Sales Q/Q	-98.74%	Earnings	Nov 13 AMC	Avg Volume	916.35K	Price	6.50
SMA20	-14.20%	SMA50	-20.04%	SMA200	-64.86%	Trades		Volume	932,249	Change	-5.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-24	Initiated	Morgan Stanley	Underweight	$8
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight	$459
Apr-15-24	Initiated	Barclays	Overweight	$45
Feb-07-24	Resumed	Goldman	Buy	$81
Oct-26-23	Initiated	RBC Capital Mkts	Outperform	$25
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$32
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform	$24
Jul-05-23	Initiated	Chardan Capital Markets	Buy	$30
Jan-30-23	Initiated	BMO Capital Markets	Outperform	$50
Nov-18-22	Initiated	H.C. Wainwright	Buy	$36
Nov-15-22	Upgrade	Goldman	Neutral → Buy	$12 → $68
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12
Jun-22-22	Initiated	Jefferies	Buy	$22
Jan-04-22	Initiated	SVB Leerink	Outperform	$30
Jan-05-21	Initiated	Goldman	Neutral	$44
Jan-05-21	Initiated	Evercore ISI	Outperform	$70
Jan-05-21	Initiated	BofA Securities	Buy	$47

Show Previous Ratings

Nov-26-24 06:51AM	4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-14-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV (GlobeNewswire)
Nov-13-24 05:20PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Sep-25-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:00AM	Loading…
Sep-23-24 08:00AM	4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-19-24 02:34PM	4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate (Benzinga) -19.74%
10:30AM	4D Molecular data bode well for eye gene therapy, but shares fall (BioPharma Dive)
Sep-18-24 04:05PM	4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day (GlobeNewswire)
Sep-05-24 08:00AM	4DMT Announces Presentations at Upcoming Retina Conferences (GlobeNewswire)
Sep-03-24 08:00AM	4DMT to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-27-24 08:00AM	4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 (GlobeNewswire)
Aug-23-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-12-24 08:00AM	4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-08-24 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Aug-05-24 08:00AM	4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board (GlobeNewswire) -5.97%
Jul-17-24 05:00AM	4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity (GlobeNewswire) -31.96%
Jul-12-24 09:40AM	4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last? (Zacks) +5.54%
Jul-08-24 05:52PM	4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock? (Insider Monkey) +5.58%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 08:00AM	4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy (GlobeNewswire)
Jun-18-24 08:00AM	4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast (GlobeNewswire)
Jun-08-24 04:30PM	4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-06-24 07:30AM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference (GlobeNewswire) -17.27%
Jun-04-24 08:00AM	4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-03-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-30-24 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47 European Cystic Fibrosis Conference (GlobeNewswire)
May-10-24 01:48PM	4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections (GuruFocus.com)
May-09-24 11:55PM	FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Loading…
04:05PM	4DMT Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
May-07-24 08:00AM	4DMT to Participate in Upcoming Investor Conference (GlobeNewswire)
May-01-24 10:01AM	4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +6.10%
08:00AM	4DMT Announces Presentations at ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 01:30AM	4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares (GuruFocus.com)
Mar-29-24 07:01PM	4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares (GuruFocus.com)
Mar-28-24 08:00AM	4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis (GlobeNewswire) -11.18%
Mar-04-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-02-24 04:32AM	4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 06:05PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4DMT Reports Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
Feb-12-24 08:00AM	4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium 2024 (GlobeNewswire)
Feb-08-24 03:05AM	Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc (GuruFocus.com)
Feb-06-24 11:27PM	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -14.97%
Feb-05-24 04:05PM	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +84.62%
02:50PM	Why Is 4D Molecular (FDMT) Stock Up 85% Today? (InvestorPlace)
12:36PM	4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' (Reuters)
Feb-03-24 05:00PM	4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD (GlobeNewswire)
Jan-29-24 08:00AM	4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden (GlobeNewswire)
Jan-25-24 10:04PM	4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares (GuruFocus.com) -8.28%
Jan-23-24 08:00AM	4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease (GlobeNewswire)
Jan-19-24 12:00PM	All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy (Zacks)
Jan-11-24 10:00AM	TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors (PR Newswire)
Jan-09-24 05:02AM	4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares (GuruFocus.com)
Jan-06-24 05:02AM	Andreas Halvorsen's Firm Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
05:02AM	Andreas Halvorsen Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
Jan-04-24 08:00AM	4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates (GlobeNewswire)
Jan-03-24 08:01AM	4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases (GlobeNewswire) -5.08%
Dec-21-23 08:00AM	4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD (GlobeNewswire) +7.35%
Dec-04-23 08:00AM	4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
Nov-15-23 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-09-23 04:19PM	4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire) +5.24%
Nov-01-23 04:00PM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC (GlobeNewswire)
Oct-30-23 08:00AM	4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy (GlobeNewswire)
Oct-26-23 09:56AM	Microsoft upgraded, F5 Networks downgraded: Wall Street's top analyst calls (The Fly)
Oct-25-23 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC (GlobeNewswire)
Oct-23-23 08:00AM	4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD (GlobeNewswire)
Sep-12-23 04:05PM	4DMT Appoints Uneek Mehra as Chief Financial and Business Officer (GlobeNewswire)
Sep-07-23 04:05PM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD (GlobeNewswire)
Aug-09-23 06:15PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
08:22AM	Despite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 year (Simply Wall St.)
Jul-29-23 12:00PM	4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023 (GlobeNewswire)
Jul-17-23 04:05PM	4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data (GlobeNewswire)
Jul-10-23 07:30PM	Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets (PR Newswire) +5.33%
Jun-08-23 09:53AM	4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why (Benzinga) +6.84%
Jun-07-23 04:10PM	4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting (GlobeNewswire)
Jun-01-23 08:00AM	4D Molecular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-24-23 08:00AM	4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting (GlobeNewswire)
May-13-23 08:27AM	Institutional investors have a lot riding on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with 44% ownership (Simply Wall St.)
May-12-23 06:02PM	Andreas Halvorsen's Firm Storms Deeper Into 4D Molecular Therapeutics (GuruFocus.com) +5.98%
06:02PM	Andreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics (GuruFocus.com)
May-11-23 08:00AM	4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-10-23 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
May-09-23 04:05PM	4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
08:25AM	Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-23 04:05PM	4D Molecular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
06:27AM	4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains? (Zacks)
May-04-23 09:04PM	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -15.46% +5.35%
04:08PM	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-27-23 04:29PM	What's Going On With 4D Molecular Therapeutics Stock Today (Benzinga) -19.79% +9.15%
07:00AM	4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023 (GlobeNewswire)
Apr-24-23 08:00AM	Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas Short-Form Human Complement Factor H (GlobeNewswire)
08:00AM	4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy (GlobeNewswire)
Apr-14-23 04:23AM	4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-13-23 08:00AM	4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer (GlobeNewswire) +11.15%
Apr-12-23 08:21AM	Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bizily Scott	Chief Legal Officer	Sep 16 '24	Option Exercise	6.49	500	3,245	7,281	Sep 18 05:46 PM
Bizily Scott	Chief Legal Officer	Sep 16 '24	Sale	16.33	500	8,165	6,781	Sep 18 05:46 PM
Bizily Scott	Chief Legal Officer	Aug 19 '24	Option Exercise	6.49	500	3,245	7,281	Aug 21 04:28 PM
Bizily Scott	Chief Legal Officer	Aug 19 '24	Sale	15.00	500	7,500	6,781	Aug 21 04:28 PM
Bizily Scott	Chief Legal Officer	Jul 16 '24	Option Exercise	7.60	1,750	13,295	8,531	Jul 18 08:22 PM
Bizily Scott	Chief Legal Officer	Jul 16 '24	Sale	27.11	1,750	47,442	6,781	Jul 18 08:22 PM
Bizily Scott	Chief Legal Officer	Jul 11 '24	Option Exercise	15.78	1,996	31,497	8,777	Jul 15 06:13 PM
Bizily Scott	Chief Legal Officer	Jul 11 '24	Sale	25.00	1,996	49,900	6,781	Jul 15 06:13 PM
Kirn David	Chief Executive Officer	Jul 10 '24	Option Exercise	14.55	12,923	188,077	1,072,076	Jul 12 05:46 PM
Kirn David	Chief Executive Officer	Jul 10 '24	Sale	22.49	12,923	290,598	1,059,153	Jul 12 05:46 PM
Bizily Scott	Chief Legal Officer	Jul 01 '24	Option Exercise	7.55	4,248	32,089	5,985	Jul 03 05:11 PM
Bizily Scott	Chief Legal Officer	Jul 01 '24	Sale	21.36	4,248	90,758	1,737	Jul 03 05:11 PM
Kirn David	Chief Executive Officer	Jun 24 '24	Option Exercise	14.42	12,930	186,451	1,072,083	Jun 26 05:07 PM
Kirn David	Chief Executive Officer	Jun 24 '24	Sale	23.10	12,930	298,711	1,059,153	Jun 26 05:07 PM
Bizily Scott	Chief Legal Officer	Jun 17 '24	Option Exercise	7.60	1,750	13,295	3,487	Jun 20 04:59 PM
Bizily Scott	Chief Legal Officer	Jun 17 '24	Sale	23.71	1,750	41,494	1,737	Jun 20 04:59 PM
Bizily Scott	Chief Legal Officer	May 16 '24	Option Exercise	7.60	1,750	13,295	3,487	May 20 08:35 PM
Bizily Scott	Chief Legal Officer	May 16 '24	Sale	25.45	1,750	44,541	1,737	May 20 08:35 PM
Bizily Scott	Chief Legal Officer	Apr 16 '24	Option Exercise	7.60	1,750	13,295	3,487	Apr 18 08:48 PM
Bizily Scott	Chief Legal Officer	Apr 16 '24	Sale	25.74	1,750	45,045	1,737	Apr 18 08:48 PM
Bizily Scott	Chief Legal Officer	Apr 01 '24	Option Exercise	12.54	8,153	102,224	9,890	Apr 03 07:18 PM
Bizily Scott	Chief Legal Officer	Apr 01 '24	Sale	31.78	8,153	259,102	1,737	Apr 03 07:18 PM
Bizily Scott	Chief Legal Officer	Mar 27 '24	Option Exercise	25.98	5,833	151,541	7,570	Mar 29 04:52 PM
Bizily Scott	Chief Legal Officer	Mar 27 '24	Sale	35.04	5,833	204,410	1,737	Mar 29 04:52 PM
Bizily Scott	Chief Legal Officer	Mar 18 '24	Option Exercise	7.60	1,750	13,295	3,487	Mar 20 04:40 PM
Bizily Scott	Chief Legal Officer	Mar 18 '24	Sale	31.27	1,750	54,722	1,737	Mar 20 04:40 PM
Bizily Scott	Chief Legal Officer	Feb 27 '24	Option Exercise	20.24	1,909	38,638	3,646	Feb 29 06:01 PM
Bizily Scott	Chief Legal Officer	Feb 27 '24	Sale	30.00	1,909	57,270	1,737	Feb 29 06:01 PM
Bizily Scott	Chief Legal Officer	Feb 16 '24	Option Exercise	7.60	1,750	13,295	3,487	Feb 21 05:41 PM
Bizily Scott	Chief Legal Officer	Feb 16 '24	Sale	27.67	1,750	48,422	1,737	Feb 21 05:41 PM
Bizily Scott	Chief Legal Officer	Feb 08 '24	Option Exercise	10.18	6,244	63,586	4,653	Feb 12 09:04 PM
Bizily Scott	Chief Legal Officer	Feb 08 '24	Sale	27.50	6,244	171,710	1,737	Feb 12 09:04 PM
Kirn David	Chief Executive Officer	Feb 08 '24	Sale	27.13	92,001	2,495,822	1,059,153	Feb 12 08:22 PM
Kim Robert Young	Chief Medical Officer	Feb 05 '24	Option Exercise	15.29	24,000	366,840	13,595	Feb 07 08:32 PM
Kim Robert Young	Chief Medical Officer	Feb 05 '24	Sale	30.05	24,552	737,788	1,043	Feb 07 08:32 PM
Kirn David	Chief Executive Officer	Jan 23 '24	Sale	18.41	5,696	104,851	1,151,154	Jan 25 04:59 PM
Kirn David	Chief Executive Officer	Jan 04 '24	Sale	20.31	40,732	827,202	1,185,087	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Jan 05 '24	Sale	19.57	28,237	552,478	1,156,850	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Dec 15 '23	Sale	17.27	28,632	494,432	1,230,521	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Dec 18 '23	Sale	18.13	4,702	85,243	1,225,819	Jan 08 04:19 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 04 '24	Sale	19.53	540,000	10,546,200	4,247,914	Jan 05 05:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FDMT

4D Molecular Therapeutics Inc

Upgrade your FINVIZ experience